BNP Paribas Financial Markets Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

BNP Paribas Financial Markets boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 346.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,433 shares of the company’s stock after acquiring an additional 8,098 shares during the period. BNP Paribas Financial Markets’ holdings in Krystal Biotech were worth $1,899,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Summit Trail Advisors LLC bought a new stake in shares of Krystal Biotech in the 3rd quarter worth about $1,893,000. Swiss National Bank raised its position in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after purchasing an additional 2,900 shares during the period. Sei Investments Co. lifted its stake in shares of Krystal Biotech by 18.9% in the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after purchasing an additional 6,363 shares during the last quarter. Shaker Investments LLC OH purchased a new position in shares of Krystal Biotech in the 3rd quarter worth approximately $532,000. Finally, Citigroup Inc. increased its position in shares of Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after purchasing an additional 13,874 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $185.25 on Friday. The firm’s 50 day simple moving average is $181.27 and its 200-day simple moving average is $184.52. Krystal Biotech, Inc. has a one year low of $101.34 and a one year high of $219.34. The firm has a market cap of $5.33 billion, a PE ratio of 104.66 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period last year, the business posted ($0.67) EPS. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. Equities research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Analysts Set New Price Targets

KRYS has been the subject of several recent analyst reports. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Evercore ISI boosted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus increased their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus price target of $202.29.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).